Skip to main content

08-04-2019 | Oncology | News | Article


FDA approves point-of-care PSA test

medwireNews: The US FDA has granted marketing approval for a point-of-care device for the measurement of prostate-specific antigen (PSA).

The Sangia Total PSA Test (OPKO Diagnostics, LLC, Woburn, Massachusetts, USA) uses a finger prick test to collect a blood sample and can generate a PSA result within 15 minutes. The test is approved for use in patients aged 50 years or older following results from a clinical trial of 434 men attending 10 different US centers.

The test may be used alongside a prostate biopsy for the diagnosis of prostate cancer.

By Lynda Williams

medwireNews is an independent medical news service provided by Springer Healthcare. © 2019 Springer Healthcare part of the Springer Nature group

Related topics

See the research in context now

with trial summaries, expert opinion and congress coverage

Image Credits